Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Surprising trading considering the recent 8-k’s. $0.29.
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split
NEW YORK, September 25, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-16 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Friday, September 27, 2024
Hits shareholders with an offering and a reverse split every single fucking time the share price goes up a little. There is no way to make money with this POS except shorting it.
Dilute dilute dilute that's all this Indian shithead knows how to do
Sorry, meant 8-K.
Where do you see a 10-K? There is nothing on EDGAR.
Form 10-K today counter acted good news.
Price dropping.
SEEL......................................https://stockcharts.com/h-sc/ui?s=SEEL&p=W&b=5&g=0&id=p86431144783
Seelos Therapeutics Says Ketamine-Based Therapy Chosen for Government PTSD Study
MT Newswires
09:00 AM EDT, 09/24/2024 (MT Newswires) -- Seelos Therapeutics (SEEL.NaE) said Tuesday its investigational ketamine-based treatment, SLS-002, was selected for inclusion in the US Department of Defense's Military and Veterans Adaptive Platform clinical trial of potential treatments for post-traumatic stress disorder.
The company said it signed a material transfer agreement with the US Army Medical Materiel Development Activity to supply SLS-002, or intranasal racemic ketamine, for the study and dosing of the SLS-002 group is expected to start before the end of the year. Financial details were not disclosed.
Seelos said SLS-002 is the only ketamine-based therapy included in the study.
Shares of the company were up more than 85% in recent Tuesday premarket activity.
Price: 0.3521, Change: +0.16, Percent Change: +85.32
Wow pumped to .50 next would have been .73 resistance but looks like dilution and shafting shareholders next
still holding gltu
out before the dump, next.
wow really is some power in this hour look at those buys
trying to draw an inside straight here on the river.. volume is nutz..just an impulse shot here 1k shares .. friday action yikes
Premarket pump jobs always tank, 95% of the time, very risky
No news on anything their science is based on, simply a pump job here! Scrap imo
Nice LOL. Nice volume too. Let's see this back over the $. https://finviz.com/quote.ashx?t=SEEL&p=d
Shs Float 2.71M
From 10Q As of August 6, 2024, 5,956,903 shares of the common stock, par value $0.001, of the registrant were outstanding.
https://ih.advfn.com/stock-market/NASDAQ/seelos-therapeutics-SEEL/stock-news/94383074/form-10-q-quarterly-report-sections-13-or-15d
Not getting my hopes us they mega dumped here.
Let's see this follow SNGX
looking at me funny now
me too- i am eyeing it closely. Took starter.
Do you give a lot of weight to the Bollinger bands in these setups?
It's certainly possible! .6055 I'd like to see this puppy pinch.
SEEL daily
Under the $ for a minute there.
Wow. No wonder why I deleted this puppy.
Followers
|
245
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
30413
|
Created
|
09/14/05
|
Type
|
Free
|
Moderators |
Seelos Therapeutics is exploring new ways to think about and treat central nervous system (CNS) disorders in neurological diseases and disorders and in rare diseases. Our trials are designed to further evaluate the safety and efficacy of our acquired assets. These come to Seelos with well characterized efficacy and safety, thereby avoiding much of the lengthy and burdensome process of preclinical R&D.
By working with clinically ready novel and reformulated compounds we will move from asset acquisition to meaningful data readouts in an expedited and efficient fashion. It is our goal to develop unique and disruptive therapies and approaches to improve treatment of large known diseases, offer new treatments for large unmet or recently characterized indications as well as advance therapies for orphan indications.
Our approach to this process will require development that is appropriate and efficient for a company our size in the scope of work each program requires in regards to trial size and duration.
We invite you to stay update on the progress of our assets in our clinical development programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |